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Objective: To explore the impact self-funding has on
patient experience of oral anticoagulation therapy self-
monitoring.
Design: Semistructured, qualitative interviews were
conducted. Transcripts were analysed thematically
using constant comparison.
Setting: England.
Participants: Interviewees were participants of the
Cohort Study of Anticoagulation Self-Monitoring
(CASM). Cohort members were recruited as they
bought a monitor from the major manufacturer in the
UK. A purposive sample was invited to be interviewed
on completion of the 12-month cohort follow-up.
Data: Patient narratives on their experiences of self-
monitoring their oral anticoagulation therapy in non-
trial conditions.
Results: 26 interviews were completed. Interviewees
viewed purchasing the monitoring device as a long-
term commitment balancing the limitations of clinic-
based monitoring against the cost. They were unable
to try out the monitor prior to purchase and therefore
had to be confident in their own ability to use it. The
variable provision of self-monitoring equipment caused
resentment, and interviewees were uncomfortable
negotiating with healthcare professionals. High test
strip usage while learning how to use the monitor
caused anxiety that was exacerbated by worries about
their cost. However, self-funding did mean that
interviewees felt a sense of ownership and were
determined to persevere to overcome problems.
Conclusions: Self-funding has negative implications
in terms of equity of access; however, the money
invested acts as a barrier to discontinuation. If oral
anticoagulation therapy self-monitoring devices and
consumables were provided free of charge in routine
care, the training and support available in England may
need to be reviewed to prevent discontinuation rates
rising to those observed in clinical trials.
BACKGROUND
Patients at increased risk of thromboembol-
ism can be given oral anticoagulation
therapy (OAT) using vitamin K antagonists
to reduce their risk. Such therapy requires
close monitoring and dose adjustment to
maximise its beneﬁts. A systematic review and
meta-analysis of trial data found that self-
monitoring improved the quality of anticoa-
gulation monitoring and reduced the risk of
thrombosis by half when compared with
clinic-based monitoring.1 Furthermore, parti-
cipants of trials reported improvements in
their quality of life.2–7
Previously, there have been concerns
regarding whether the positive effects found
in OAT self-monitoring trials translate into
real-life settings. To help address these uncer-
tainties, we conducted a prospective cohort
study in the UK (the Cohort Study of
Anticoagulation Self-Monitoring (CASM)),
which found that individuals can successfully
self-monitor their OAT outside of clinical
trials, achieving high levels of anticoagulation
control and few adverse events,8 a ﬁnding
replicated elsewhere.9–11 As part of the
CASM study, participant interviews revealed
that although self-monitoring made a posi-
tive impact on their lives, better health
service support would have alleviated some
problems.12 An unanticipated ﬁnding from
Strengths and limitations of this study
▪ Qualitative methods allowed an in-depth insight
into the patient experience of self-monitoring
their oral anticoagulation therapy.
▪ Patients were self-monitoring in ‘real-life’ and not
in trial conditions.
▪ Interviews were conducted at the end of the
12-month cohort follow-up and the passing of
time may have shaped their recollections regard-
ing beginning to self-monitor.
▪ Given the cost of self-monitoring, interviewees
tended to be well educated and from less
deprived neighbourhoods and so not representa-
tive of all patients that could be offered
self-monitoring.
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the interviews was the extent to which self-funding had
shaped their experiences.
In England, OAT self-monitoring is a minority activity:
most patients attend anticoagulation monitoring clinics
either at their local General Practitioner (GP) Surgery
or hospital. OAT self-monitoring devices are not pro-
vided by the National Health Service (NHS) and so
patients wishing to self-monitor obtain them directly for
∼£400. The provision of the consumables required—
including the single-use test strips on prescription (ie,
heavily subsidised if not free)—and self-monitoring
training varies depending under which NHS Clinical
Commissioning Group (previously known as a Primary
Care Trust) the patient falls. Access to OAT self-
monitoring in England is therefore dependent on the
patient’s ability to pay for it. We could not ﬁnd any previ-
ous in-depth reports in the literature of the effect that
funding support has on patient experience of self-
monitoring and therefore decided to present this theme
separately from the main qualitative ﬁndings12 to enable
a full description.
METHODS
The full methods and results of the CASM study are
published elsewhere.8 Brieﬂy, 296 people who had
decided to self-monitor their OAT were recruited as they
purchased a monitor (the Roche Coaguchek S or XS)
either as a ﬁrst or replacement model. Participants were
followed up for 12 months with qualitative interviews
being conducted at the end of this period in a sample
of cohort members approached by telephone. A purpos-
ive sampling strategy—based on age, gender, condition
requiring OAT, duration of self-monitoring, primary or
secondary care setting for anticoagulation management
and dose adjustment system—was used to ensure that a
range of experiences were studied.13 An interview sched-
ule was developed based on the literature and issues that
had arisen during the quantitative cohort follow-up.8
Analysis ran concordantly with data collection to allow
reﬁnement of this schedule. All interviews were con-
ducted by the same non-clinical researcher trained in
qualitative research methods (AT) on a one-to-one basis.
They were digitally recorded, transcribed and checked
to ensure accuracy. The software NVIVO (QSR
International) was used to organise the interview tran-
scripts and the coding framework.14 Initial coding was
undertaken independently by two researchers to ensure
that all areas were covered and reﬁned using the con-
stant comparison method.15 Both novel and anticipated
themes emerging from the transcripts were investigated.
Recruitment continued until thematic saturation
occurred.
RESULTS
In total, 26 of the 34 CASM participants approached
agreed to be interviewed. Interviews were conducted
between November 2011 and November 2012 and lasted
between 30 and 75 min in duration. Nineteen interviews
were face-to-face (17 at the interviewees’ homes, two in
their workplace); the remaining seven interviews were
conducted on the telephone. The sample had a median
age of 54 years (range 32–87 years) and comprised of 10
men (38.5%). The majority had either a professional
(11, 42.3%) or university qualiﬁcation (9, 34.6%) and
tended to live in less deprived neighbourhoods (median
Index of Multiple Deprivation Score 2010 of 10.4).12
Most interviewees (11, 42.3%) required anticoagulation
due to previous thrombosis; eight (30.8%) due to
having a mechanical heart valve; four (15.4%) because
of atrial ﬁbrillation and three (11.5%) had antiphospho-
lipid syndrome.
Interviewees described how self-funding shaped each
stage of their self-monitoring journey from the initial
decision to self-monitor and gaining the support
required to begin, to motivating them to continue.
Throughout this journey, self-funding altered the per-
ceived value of their activities and severity of their condi-
tion. Figure 1 describes the themes reported in this
paper.
Starting to self-monitor—the monitor as an investment
Interviewees described balancing the expense of the
monitor with the various costs associated with attending
the clinic: “Finance is an issue, but then you’ve got to
weigh that up with travelling and petrol and going in
the car and waiting, and there’s a cost to all that”
(ID332, woman, 66 years). Owing to the price of the
testing device, beginning self-monitoring was felt to be a
long-term commitment: “If I wasn’t a lifer [taking war-
farin indeﬁnitely] I wouldn’t have got one, there would
have been no point, it just would have been a waste of
money but knowing that I am a lifer then it’s worth the
money” (ID369, woman, 41 years).
Interviewees researched the device prior to purchase,
sometimes using the internet or making contact with
other patients already self-monitoring: “I think it’s a
chance you’ve got to take…You’ve got to sort of say, ‘Is it
going to work? And how does it work? And is it going to
be any good to me?’ And if it is, well, you go ahead and
have a go at it…yes, it is expensive. That is the one thing
about it. But I think it’s worth it” (ID351, woman,
73 years). They were rarely able to gain any practical
experience of using the monitor prior to its purchase:
“What might have been better is if there had been a
Figure 1 Themes relating to the impact of self-funding on
anticoagulation self-monitoring.
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system to rent or hire a machine, borrow machine for a
period of time just to try it out to see how you get on
with it” (ID379, man, 46 years). They, therefore, had to
be conﬁdent in their own ability to operate it—for
example, being dexterous enough to prick their own
ﬁnger or read the monitor display—in order to invest: “I
might have spent £300 and I couldn’t use it but that was
my decision and that puts people off, the price” (ID307,
woman, 59 years).
The decision to spend the money was made in the
context of their lives: “I thought well I haven’t got that
straightaway, it’s gonna take me time to earn that, I
mean now we’ve got six children” (ID263, woman,
54 years). For some, the cost required periods of saving
or sacriﬁce: “If somebody’s had a stroke and they’re out
of work and they’ve not got any ﬁnancial back-up
system, £300 or £400…it seems too much money”
(ID307, woman, 59 years). The interest free repayment
scheme or special discounts offered by the monitor
manufacturer were welcomed: “I’m paying for the actual
thing, you know, I had it over the year. Thank goodness,
it was zero interest” (ID340, woman, 78 years).
Starting self-monitoring—negotiating support
Interviewees were largely resigned to funding their own
monitor. However, the uncertainty surrounding the
supply of consumables on prescription caused concern
when arranging to start self-monitoring: “They did say
before you get one [monitoring device] make sure your
GP will prescribe the test strips and the lancets because
a lot of them don’t, which is what I did ﬁrst, I did speak
to the doctors ﬁrst and then they had a meeting and
they decided they would so then I went ahead and
ordered one” (ID369, woman, 41 years). Having rationa-
lised the cost of the testing device by intending to self-
monitor for a continued period, the cost of testing con-
sumables required would not be insigniﬁcant: “If I’d of
have had to buy the test strips as well I would have
thought twice about it. The fact that I could get those
on prescription and the lancets as well means the
running costs, apart from batteries, are negligible to
me” (ID379, man, 46 years).
Those in contact with patient support groups entered
into negotiations for testing consumables on prescrip-
tion conscious that their healthcare professional may
decline their request. The decision of the local commis-
sioning body was often delivered by interviewees’ GPs:
“They don’t prescribe the strips in this area because it’s
a postcode lottery…but my GP told me that at the begin-
ning” (ID339, woman, 49 years). The negotiations took
place amid ongoing healthcare sometimes causing
anxiety: “I was so upset the way that I’ve been spoken to,
I’m too frightened they’ll mark my card and get rid of
me from their surgery” (ID281, woman, 42 years).
Several interviewees reported changing healthcare pro-
fessional or conversely delayed moving in order to be
able to access support to self-monitor: “I don’t think any
patient should be involved in politics really and I feel
that I’ve very much been…in the difﬁcult position of… I
don’t like facing conﬂict face-to-face, I mean very few of
us do” (ID350, man, 32 years).
When negotiating the supply of testing consumables,
interviewees described their healthcare professionals as
apprehensive of excessive testing: “The only thing that
was worrying her [the GP] was whether I would get a bit
obsessive about doing the ﬁnger prick constantly and
therefore asking her to pay for rather expensive…test
strips” (ID293, woman, 73 years). Owing to these con-
cerns, some healthcare professionals rationed the
supply: “I’m allowed to have twenty-four a year from
them [the GP surgery]” (ID369, woman, 41 years).
Starting self-monitoring—the cost of learning
All interviewees described an initial period of mastering
how to apply blood to the test strip correctly. During this
time, a number of strips were wasted and usage was
higher than expected: “I got cross, I got upset. Not just
because of the price of the strip, but because I couldn’t
do it and I wanted to know why” (ID351, woman,
73 years). Those that paid for their own strips experi-
enced the consequential costs directly: “I ﬂoundered at
ﬁrst…I kept thinking, ‘Oh not another strip, I’ve got to
use another strip, they’re so expensive’’’ (ID340, woman,
78 years). Those that received their test strips on NHS
prescription were worried that this initial high consump-
tion would lead to this privilege being withdrawn: “I
remember, every time I wasted a strip, I felt very angry
because I was in a context of feeling that the supply of
strips was very limited and the doctor wasn’t happy to
give them to me” (ID350, man, 32 years). Once the
initial learning period had passed, interviewees were
able to use the monitor more reliably and strip usage
decreased.
Maintaining self-monitoring—altering behaviour
Among our sample, there was limited evidence that
having to pay for the test strips restricted the amount
they were able to test: “It will get to the point where you
think, ‘I’m not going to do it because I can’t test when I
should be because I can’t afford to do it’. So that’s what
worries me long term” (ID281, woman, 42 years). More
typical—among this relatively afﬂuent group—was that
by self-funding interviewees felt able to disregard health-
care professional advice and test more frequently in
order to keep a closer eye on their anticoagulation
status: “I’m paying for the strips, so [laughs] they
wouldn’t know whether I was doing it or not!” (ID351,
woman, 73 years).
Maintaining self-monitoring—vulnerability to change
Among those that had successfully negotiated to receive
test strips, there was an apprehension that this decision
was temporary: “I was actually managing to get the strips
through negotiation, but a little thing like when I went
to ﬁll in the repeat prescription forms, they were never
listed there for me to tick, I had to actually write on the
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form ‘and I need some test strips’…it felt each time
that I was almost being given them as goodwill and it
was going to end soon” (ID350, man, 32 years). A
handful of interviewees reported that the decision to
supply test strips on prescription was subsequently
reneged by the Clinical Commissioning Group citing
ﬁnancial pressures. Interviewees were not consulted
about these decisions and felt passive in this process:
“They’ve never discussed the matter with me before
writing a letter saying, ‘There’s the guillotine’” (ID211,
man, 78 years).
Maintaining self-monitoring—responsibility of ownership
With patients owning their testing device and their antic-
oagulation clinic using the results, taking responsibility
for ensuring accuracy of the monitor was a grey area.
Following a calibration check in which her monitor was
compared to a venous test at the clinic, one interviewee
described how neither the manufacturer nor the clinic
were willing to help her resolve the large difference
between results: “He [the manufacturer representative]
would not admit that there could be anything wrong
with the machine, that it had to be at the hospital’s end”
(ID263, woman, 54 years). Self-monitoring contracts
between clinics and patients to set out roles and respon-
sibilities were valued. However, not all interviewees had
these or they did not include responsibility for resolving
accuracy issues. Interviewees also reported uncertainty
about the lifespan of their monitor: “Does it get inaccur-
ate after a period of time?…How long does it
last?”(ID352, man, 55 years); “I checked the warranty of
it because this is another factor, fortunately it has a two
year warranty which if it packs up what do you then do?”
(ID239, man, 68 years).
Maintaining self-monitoring—a barrier to discontinuation
While self-funding had implications in terms of equity of
access, it meant that interviewees were determined to
persevere. For example, when encountering problems
using the monitor initially, interviewees felt compelled
to continue: “Let’s just keep going…and we’d also spent
whatever it was” (ID342, man, 48 years). For those who
had had their supply of test strips on prescription dis-
continued, by this point they had purchased their
testing device and often established self-monitoring rou-
tines. Given the amount of time, effort and money
already invested they felt they had little choice but to
incur the additional costs and to continue to self-
monitor. “I’d stick with the machine now…I’ve paid for
the machine” (ID387, man, 47 years).
The value of self-monitoring
The variation in the support OAT self-monitoring
patients received caused resentment: “I know you can’t
put a price on your health but when it is available on
prescription and everybody else gets it that’s when it’s
unfair” (ID281, woman, 42 years). The situation was
often contrasted against that for diabetes: “The test
strips aren’t exactly cheap but then diabetics get every-
thing, they get all their stuff for free don’t they? So why
can’t we have a helping hand then?” (ID369, woman,
41 years). Some felt that diabetes was therefore viewed
as more serious: “They don’t think that having a blood
clotting disorder is life threatening, how can that not
be? Diabetes is life threatening but I’m sorry, the blood
that I’ve got is also, you know, life threatening” (ID357,
woman, 55 years). Others highlighted the similarities on
the impact to their lives: “It’s [Warfarin’s] like being on
insulin, that’s a good comparison really because insulin
you have to take every day, Warfarin for life you take
every day. They’re both quite dangerous materials”
(ID307, woman, 59 years).
Interviewees felt that the beneﬁts to the NHS of their
self-monitoring activities were unacknowledged and
unappreciated: “You’re taking over the hospital’s role
and you’re funding it yourself, they’re saving money on
you but you’re paying for it” (ID281, woman, 42 years).
This included taking responsibility for monitoring their
long-term health condition and avoiding adverse events:
“Get a monitoring kit and you’ve got to control that and
do your bit towards the NHS really by not going to cas-
ualty phlebotomy clinic you’re saving a lot of money and
also your own time” (ID307, woman, 59 years). By
declining to fund it, it was felt that the NHS did not
value the effort they expended self-monitoring.
DISCUSSION
Summary
The CASM study sought to explore the factors that
predict success and failure in self-monitoring of OAT
outside of clinical trial conditions. We anticipated that
psychological and social factors would be important.
While they played a role, we found that in the ‘real
world’ the variable healthcare support available was key
in shaping patient experience, an important aspect of
which was the provision of the equipment and consum-
ables required.8 12
Unlike clinical trial participants, interviewees pur-
chased their own monitor. The price caused careful
reﬂection on their ability to self-monitor and possibly ﬁl-
tered out those less determined or lacking self-efﬁcacy.
Interviewees felt a sense of ownership and the money
invested acted as a barrier to discontinuation especially
during the problematic initial stages. The cost of the test
strips caused anxiety, especially when usage was higher
while the correct testing technique was learnt.
Strengths and limitations
The qualitative component of the CASM study is the
ﬁrst to investigate in depth the patient experience of
OAT self-monitoring in a non-trial, UK setting.
Participants were interviewed about their experiences at
the end of the 12-month cohort follow-up and it is pos-
sible that the passing of time altered their recollections
of starting to self-monitor. Unsurprisingly, given the cost
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of the monitor, interviewees typically lived in less
deprived neighbourhoods and are not representative of
all anticoagulation patients that could self-monitor.
Therefore, while it has not been possible to study the
full breadth of the impact patient self-ﬁnancing could
have on patient experience of self-monitoring, the study
provides an insight into this previously unreported area.
Since this study was conducted, the use of novel oral
anticoagulants in clinical practice has increased. This
class of drugs offers an alternative for patients not
wishing to attend regular monitoring appointments or
to self-monitor. However, they are not suitable for
patients with severe kidney disease, impaired liver func-
tion or a prosthetic heart valve.16 Furthermore, some
patients may be reluctant to switch due to the lack of
commercially available antidotes for some novel oral
anticoagulants17 meaning that self-monitoring will con-
tinue to play a role in anticoagulation management.
Comparison with existing literature
Among our relatively afﬂuent sample, there was very
limited evidence of self-testing frequency being altered
by concerns about cost. This is in contrast with several
studies of patients with diabetes conducted in health
systems where self-monitoring consumables were not
supplied free of change. Non-adherent self-monitoring
was found in patients with higher out-of-pocket costs for
glucometer strips in California18 while the price of test
strips was identiﬁed as a major barrier to self-monitoring
in Trinidad and Tobago19 and Malaysia.20 A qualitative
study conducted in Canada found evidence of patients
rationing test strips and reusing lancets in order to
reduce costs.21
It is recognised that self-management can be hard
work for patients, even with well-developed support
systems in place.22 Along with the more typical chal-
lenges of learning a new skill and developing a
routine,12 our interviewees expended additional effort
and energy trying to gain healthcare professional
support and the equipment required to be able to
self-monitor.
While self-funding may deter all but the most commit-
ted patients from attempting to self-monitor their OAT,
it also means that access to the clinical and broader ben-
eﬁts is limited to those that can afford to do so.
Restricting access to those patients able to pay rather
than those with the most to gain from self-monitoring is
inequitable and sits uncomfortably against the founding
principles of the NHS, a system intended to be free at
the point of delivery.
Implications for practice and research
Anticoagulation clinics in England could offer patients
an opportunity to try a monitor prior to purchase to
make their subsequent investment less of a gamble. In
terms of the consumables required, focusing on the cost
of testing strips places an additional burden on patients
learning how to use the monitor. Patients need
reassurance that this learning phase is normal, and allow-
ance should be made if calculating the initial ‘ration’ of
test strips. Hands-on training could be more widely
offered in England so that the correct technique can be
mastered with minimal stress. The use of privately funded
monitors within the context of ongoing NHS care is a
relatively new phenomenon and creates some difﬁcul-
ties.23 Further guidance regarding who is responsible for
ensuring the accuracy of the testing devices and resolving
any technical problems is required. This information
could be added to the self-monitoring contracts patients
are required to sign by some anticoagulation clinics.
If testing devices were to be provided by the NHS in
England, the variable availability of training schemes
and the robustness of support systems should be
reviewed. While the current arrangements appear
adequate for the highly motivated patients who are able
to overcome the existing barriers in place to begin self-
monitoring, this may not be the case if access is made
easier. Improved support would help prevent discontinu-
ation rates rising to those observed in clinical trials of
OAT self-monitoring.24 Future studies could investigate
healthcare systems in which anticoagulation self-
monitoring equipment is provided for patients—such as
Germany—to help inform the design of this support.
The impact of the provision of self-monitoring equip-
ment to trial participants in other conditions such as
hypertension could also be explored to improve the gen-
eralisability of research ﬁndings to clinical practice.
Acknowledgements This study would not have been possible without the
study volunteers, who generously donated their time. The authors also thank
the study’s advisory panel (Eve Knight, Co-Founder and Chief Executive of
AntiCoagulation Europe; Christian Schaefer, President of International
Self-Monitoring Association of Oral Anticoagulated Patients; Bob Vause,
patient representative; Ellen Murray, Senior Lecturer at the University of
Birmingham) and Sally Tyndel and Sian Harrison formerly research officers at
the University of Oxford.
Contributors AW and CH conceptualised the study. AW, CH, DF and SS
participated in the protocol design. AT conducted the interviews, analysed the
results and drafted the manuscript. All authors read and approved the final
manuscript.
Funding The study was supported by the National Institute for Health
Research (NIHR) Research for Patient Benefit grant (PB-PG-0408-15191) and
from the NIHR National School for Primary Care Research.
Disclaimer This report presents independent research commissioned by the
NIHR. The views expressed in this publication are those of the author(s) and
not necessarily those of the NHS, the NIHR or the Department of Health. The
funding body had no role in study design; collection, analysis or interpretation
of data; writing the manuscript; or the decision to submit.
Competing interests None declared.
Patient consent Obtained.
Ethics approval The study was approved by Berkshire Research Ethics
Committee (08/H0505/142).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Declaration of transparency The lead author affirms that this manuscript is
an honest, accurate and transparent account of the study being reported; that
no important aspects of the study have been omitted; and that any
Tompson A, et al. BMJ Open 2016;6:e013123. doi:10.1136/bmjopen-2016-013123 5
Open Access
group.bmj.com on November 27, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
discrepancies from the study as planned (and, if relevant, registered) have
been explained.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral
anticoagulation: systematic review and meta-analysis of individual
patient data. Lancet 2012;379:322–34.
2. Sawicki PT. A structured teaching and self-management program for
patients receiving oral anticoagulation: a randomized controlled trial.
Working Group for the Study of Patient Self-Management of Oral
Anticoagulation. JAMA 1999;281:145–50.
3. Verret L, Couturier J, Rozon A, et al. Impact of a pharmacist-led
warfarin self-management program on quality of life and anticoagulation
control: a randomized trial. Pharmacotherapy 2012;32:871–9.
4. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation
self-management and management by a specialist anticoagulation
clinic: a randomised cross-over comparison. Lancet 2000;356:97–102.
5. Gadisseur AP, Kaptein AA, Breukink-Engbers WG, et al. Patient
self-management of oral anticoagulant care vs. management by
specialized anticoagulation clinics: positive effects on quality of life.
J Thromb Haemost 2004;2:584–91.
6. Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of
international normalized ratio on clinical events. N Engl J Med
2010;363:1608–20.
7. McCahon D, Murray ET, Murray K, et al. Does self-management of
oral anticoagulation therapy improve quality of life and anxiety?
Fam Pract 2011;28:134–40.
8. Ward A, Tompson A, Fitzmaurice D, et al. Cohort study of
Anticoagulation Self-Monitoring (CASM): a prospective study of its
effectiveness in the community. BJGP 2015;65:e428–37.
9. Nagler M, Bachmann LM, Schmid P, et al. Patient self-management
of oral anticoagulation with vitamin K antagonists in everyday
practice: efficacy and safety in a nationwide long-term prospective
cohort study. PLoS ONE 2014;18:e95761.
10. Nilsson H, Grove EL, Larsen TB, et al. Sex differences in treatment
quality of self-managed oral anticoagulant therapy: 6,900
patient-years of follow-up. PLoS ONE 2014;9:e113627.
11. Schaefer C, Wuillemin WA, Kessels A, et al. Predictors of
anticoagulation quality in 15834 patients performing patient
self-management of oral anticoagulation with vitamin K antagonists
in real-life practice: a survey of the International Self-Monitoring
Association of Orally Anticoagulated Patients. Br J Haematol
2016;175:677–85.
12. Tompson A, Heneghan C, Fitzmaurice D, et al. Supporting patients
to self-monitor their oral anticoagulation therapy: recommendations
based on a qualitative study of patients’ experiences. Br J Gen Pract
2015;65:e438–46.
13. Coyne IT. Sampling in qualitative research. Purposeful and
theoretical sampling; merging or clear boundaries? J Adv Nurs
1997;26:623–30.
14. Gale N, Heath G, Cameron E, et al. Using the framework method for
the analysis of qualitative data in multi-disciplinary health research.
BMC Med Res Methodol 2013;13:117.
15. Glaser B, Strauss A. The discovery of grounded theory: strategies
for qualitative research. Chicago: Aldine Publishing Company, 1967.
16. National Institute for Health and Care Excellence. Clinical
Knowledge Summaries Anticoagulation—oral. October 2015. http://
cks.nice.org.uk/anticoagulation-oral (accessed 13 Sep 2016).
17. Wild D, Murray M, Donatti C. Patient perspectives on taking vitamin
K antagonists: a qualitative study in the UK, USA and Spain. Expert
Rev Pharmacoecon Outcomes Res 2009;9:467–74.
18. Karter AJ, Ferrara A, Darbinian JA, et al. Self-monitoring of
blood glucose: language and financial barriers in a
managed care population with diabetes. Diabetes Care
2000;23:477–83.
19. Ezenwaka CE, Olukoga A, Onuoha P, et al. Perceptions of
Caribbean type 2 diabetes patients on self-monitoring of blood
glucose. Arch Physiol Biochem 2012;118:16–21.
20. Ong WM, Chua SS, Ng CJ. Barriers and facilitators to
self-monitoring of blood glucose in people with type 2 diabetes
using insulin: a qualitative study. Patient Prefer Adherence
2014;8:237–46.
21. Gucciardi E, Fortugno M, Senchuk A, et al. Self-monitoring of
blood glucose in Black Caribbean and South Asian
Canadians with non-insulin treated Type 2 diabetes mellitus: a
qualitative study of patients’ perspectives. BMC Endocr Disord
2013;13:46.
22. Hinder S, Greenhalgh T. “This does my head in”. Ethnographic study
of self-management by people with diabetes. BMC Health Serv Res
2012;12:83.
23. O’Dowd A. The “self funding” NHS patient: thin end of the wedge?
BMJ 2012;345:e5128.
24. Heneghan C, Perera R, Ward A, et al. Assessing differential attrition
in clinical trials: self-monitoring of oral anticoagulation and type II
diabetes. BMC Med Res Methodol 2007;7:18.
6 Tompson A, et al. BMJ Open 2016;6:e013123. doi:10.1136/bmjopen-2016-013123
Open Access
group.bmj.com on November 27, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
qualitative study
of oral anticoagulation self-monitoring: a 
Impact of self-funding on patient experience
Alison Ward
Alice Tompson, Carl Heneghan, Stephen Sutton, David Fitzmaurice and
doi: 10.1136/bmjopen-2016-013123
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/12/e013123




This article cites 22 articles, 3 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections





To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on November 27, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
